Company intelligence / Profile preview

创健医疗

Changzhou, Jiangsu, Chinatrautec.com.cn ↗
Ownership
Private
Development stage
Other
01

Overview

创健医疗已实现重组胶原蛋白(包括I型、II型、XVII型)的标准化发酵规模生产,多个产品在损伤修复、烧伤治疗等领域已完成临床研究并进入市场,部分植入剂产品正处于临床试验阶段[1][2][4][5].

Therapeutic areas
DermatologyOther
Modalities
Recombinant proteinNucleic acidBiologic
Industry
Biotech
02

Drug pipeline

3 assets

Mini ReCol

Preclinical

2 more assets in the full pipeline.

03

Partnerships

Collaborations with national research initiatives, details of industrial partners not disclosed

Beyond the preview

Go deeper on 创健医疗.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 创健医疗.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call